Full metadata record
DC FieldValueLanguage
dc.creatorGarcía-Rodríguez, J. (Javier)-
dc.creatorCastañon, E. (Eduardo)-
dc.creatorPerez-Gracia, J.L. (Jose Luis)-
dc.creatorRodriguez, I. (Inmaculada)-
dc.creatorViudez, A. (A.)-
dc.creatorAlfaro, C. (Carlos)-
dc.creatorOñate, C. (Carmen)-
dc.creatorPerez, G. (Guiomar)-
dc.creatorRotellar, F. (Fernando)-
dc.creatorInoges, S. (Susana)-
dc.creatorLopez-Diaz-de-Cerio, A. (Ascensión)-
dc.creatorResano, L. (Leyre)-
dc.creatorPonz-Sarvise, M. (Mariano)-
dc.creatorRodriguez-Ruiz, M.E. (María Esperanza)-
dc.creatorChopitea, A. (Ana)-
dc.creatorVera, R. (Ruth)-
dc.creatorMelero, I. (Ignacio)-
dc.identifier.citationGarcía-Rodríguez, J. (Javier); Castañon, E. (Eduardo); Perez-Gracia, J.L. (Jose Luis); et al. "A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis". JOURNAL FOR IMMUNOTHERAPY OF CANCER. 6, 2018, 96es_ES
dc.description.abstractSurgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8. 74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88).es_ES
dc.description.sponsorshipFinancial support was from Instituto Carlos III (EC10–113 and TRA 007) and Fundacion BBVA.es_ES
dc.publisherNational Library of Medicinees_ES
dc.subjectDendritic celles_ES
dc.subjectColon canceres_ES
dc.subjectRelapse preventiones_ES
dc.subjectRandomized clinical triales_ES
dc.titleA randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasises_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dadun.citation.publicationNameJOURNAL FOR IMMUNOTHERAPY OF CANCERes_ES

Files in This Item:
815.06 kB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.